Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

Z-902

Supelco

Zopiclone-D4 solution

100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C17H13ClN6O3D4
Numero CAS:
1435933-78-0
Peso molecolare:
392.83
Numero CE:
200-835-2
Numero MDL:
MFCD16295185
Codice UNSPSC:
41116107
ID PubChem:
329831620
NACRES:
NA.24

Grado

certified reference material

Forma fisica

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

100 μg/mL in acetonitrile

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

O=C1C2=NC=CN=C2C(OC(N3C([2H])([2H])CN(C)CC3([2H])[2H])=O)N1C4=NC=C(Cl)C=C4

InChI

1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/i8D2,9D2
GBBSUAFBMRNDJC-LZMSFWOYSA-N

Categorie correlate

Descrizione generale

This internal standard is suitable for many LC/MS and GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or isotope dilution methods. Zopiclone is a non-benzodiazepine hypnotic sold under the trade names Imovane® and Zimovane and is prescribed for the treatment of insomnia.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Imovane is a registered trademark of Sanofi-Aventis
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

FlameExclamation mark
GHS02,GHS07

Avvertenze

Danger

Indicazioni di pericolo

H225,H302 + H312 + H332,H319

Classi di pericolo

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

35.6 °F - closed cup

Punto d’infiammabilità (°C)

2 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

O A H Reneerkens et al.
Psychopharmacology, 225(2), 303-312 (2012-08-03)
Sensory gating is an adaptive mechanism of the brain to prevent overstimulation. Patients suffering from clinical disorders such as Alzheimer's disease or schizophrenia exhibit a deficit in gating, which indicates not only an impairment in basic information processing that might
I A Korneev
Urologiia (Moscow, Russia : 1999), (2)(2), 106-108 (2013-06-26)
The arsenal of professionals providing assistance to men with erectile dysfunction includes a new, mouth dissolving dosage form of the vardenafil--levitra ODT. This form is effective, safe, and has a higher bioavailability as compared to vardenafil in the form of
Kristina Y Rust et al.
Therapeutic drug monitoring, 34(6), 729-735 (2012-11-07)
Phosphodiesterase type 5 inhibitors such as sildenafil, vardenafil, and tadalafil are a class of drugs used primarily in the treatment of erectile dysfunction. Sildenafil and tadalafil are also approved for the treatment of pulmonary hypertension. The aim of this study
JinQiu Yuan et al.
European urology, 63(5), 902-912 (2013-02-12)
Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy for erectile dysfunction (ED), but available studies investigating the comparative effects of different PDE5-Is are limited. To compare the efficacy and safety of different classes of oral PDE5-Is for ED.
Osama Shaeer
The journal of sexual medicine, 10(2), 532-540 (2012-10-24)
Utility of phosphodiesterase inhibitors (PDEi's) for the treatment of erectile dysfunction (ED) has been the focus of experimental and clinical studies. However, public preferences, attitudes, and experiences with PDEi's are rarely addressed from a population/epidemiology viewpoint. The Global Online Sexuality
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.